The risk for lung cancer incidence with calcium channel blockers:

A systematic review and meta-analysis of observational studies

Author details:
Victoria Rotshild¹, Laurent Azoulay², Majd Zarifeh³, Reem Masarwa¹, Bruria Hirsh- Raccah¹, Amichai Perlman¹, Mordechai Muszkat⁴, Ilan Matok¹

1 - Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
2 - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Department of Epidemiology, Biostatistics, and Occupational Health and Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada.
3 - Hadassah Braun School of Public and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
4 - Department of Medicine, Hadassah University Hospital Mt. Scopus, Jerusalem, Israel.

Corresponding author:
Ilan Matok, PhD
Senior Lecturer in Clinical Pharmacy
Head, Pharmacoepidemiology Research Lab
Institute for Drug Research, School of Pharmacy
Faculty of Medicine
The Hebrew University of Jerusalem

T +972.2.6757578 | M +972.54.4738508 | F +972.2.6757246
Ilan.Matok@ekmd.huji.ac.il
Address: Division of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, P.O.B 12065, Jerusalem 9112001, Israel
Summary of risk ratios for lung cancer in CCB users versus non-CCB users. Each row represents the estimated risk ratio surrounded by 95% CI calculated by random-effects model, with one study removed each time. (CCB – calcium channel blocker; CI - confidence interval)
References


